Nycomed’s clinical pipeline features promising projects with high medical utility. We are operating a full R&D organisation, developing and supporting projects from early research to life cycle management. To fill our pipeline, we are looking to work with partners, combining Nycomed's strengths in development, regulatory and commercialisation with innovative ideas from biotechs and other pharmaceutical companies.
| Name |
Molecule type |
Mechanism of action |
Area / Indication |
Partner |
| Registration |
|
| Alendronate effervescent |
Small molecule |
Effervescent bisphosphonate |
Osteoporosis |
EffRx |
| Teduglutide (Revestive®) |
Peptide |
Analogue of human glucagon-like peptide (GLP-2) |
Gastroenterology /
Short Bowel Syndrome |
NPS |
| Ciclesonide HFA nasal |
Small molecule |
Inhaled corticosteroid |
Respiratory / allergic rhinitis |
Sunovion (Sepracor) |
| Phase III |
| |
|
|
|
|
| Phase II |
| Veltuzumab |
Monoclonal antibody |
Anti CD20 antibody |
Inflammation / rheumatoid arthritis |
Immunomedics |
Saber™-
bupivacaine |
Small molecule |
Prolonged release of bupivacaine |
Pain / incisional pain |
Durect |
| Phase I |
| MT203 |
Monoclonal antibody |
Neutralizes GM-CSF |
Inflammation |
Micromet |
| PDE4i |
Small molecule |
PDE4 inhibitor |
Inflammation |
|
| PDE4i |
Small molecule |
PDE4 inhibitor |
Respiratory |
|